{"commentary":{"count":29,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18,"youtube":6,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04162210\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DREAMM-3","nct_id":"NCT04162210","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dreamm-3-nct04162210. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"DREAMM-3","arms":[{"description":"Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W","label":"Participants receiving Belantamab mafodotin","type":"EXPERIMENTAL"},{"description":"Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.","label":"Participants receiving pom/dex","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-03-11","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":325,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Belantamab mafodotin","type":"DRUG"},{"name":"Pom/dex (Pomalidomide plus low dose Dexamethasone)","type":"DRUG"}],"last_update":"2026-07-01","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2022-09-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)","timeFrame":"Up to 27 months"}],"references":[{"citation":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.","pmid":"37793771","type":"DERIVED"}],"start_date":{"date":"2020-04-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","url":"https://clinicaltrials.gov/study/NCT04162210"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dreamm-3-nct04162210"}